Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal

ABSTRACT: ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal

PROVIDER: PRJEB44103 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5646990_1.fastq.gz	Fastqsanger.gz
	ERR5646990_2.fastq.gz	Fastqsanger.gz
	ERR5646991_1.fastq.gz	Fastqsanger.gz
	ERR5646991_2.fastq.gz	Fastqsanger.gz
	ERR5646992_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib for 35 days followed by drug withdrawal

Project description:To investigate whether changes to chromatin accessibility associated with resistance to lapatinib are a stable or a reversible state, we treated OE19 cells with 500 nM lapatinib for 35 days and then withdrew lapatinib for 1, 2, 3 and 14 days. Control cells treated with DMSO for 1 day and 'resistant' cells treated with 500 nM lapatinib for 35 days were also sequenced.

2022-09-26 | E-MTAB-10314 | biostudies-arrayexpress

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to chromatin accessibility associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10302 | biostudies-arrayexpress

RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:To investigate changes to gene expression associated with resistance to lapatinib, we performed ATAC-seq on OE19 cells treated with 500 nM lapatinib for 1, 7 and 35 days and vehicle control (DMSO) for 1 day.

2022-09-26 | E-MTAB-10304 | biostudies-arrayexpress

ChIP-seq of PPARGC1A in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq for PPARGC1A was performed in OE19 cells to identify genomic binding sites. Cells were treated with 500 nM lapatinib for 48 hours.

2022-09-26 | E-MTAB-11300 | biostudies-arrayexpress

ChIP-seq of PPARGC1A in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq of PPARGC1A in oesophageal adenocarcinoma OE19 cells treated with lapatinib

| PRJEB49950 | ENA

ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:ATAC-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

| PRJEB44078 | ENA

RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

Project description:RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib

| PRJEB44079 | ENA

ChIP-seq of HNF4A, PPARGC1A and H3K27ac in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq for HNF4A, PPARGC1A and H3K27ac was performed in OE19 cells to identify genomic binding sites. Cells were treated with DMSO or 500 nM lapatinib for 48 hours.

2022-09-26 | E-MTAB-10319 | biostudies-arrayexpress

RNA-seq of human oesophageal adenocarcinoma OE19 cell line following PPARGC1A knock-down and 24 hour lapatinib treatment

Project description:To determine genes regulated by the transcriptional co-activator PPARGC1A in OAC cells and whether PPARGC1A activity is altered by lapatinib we performed RNA-seq on OE19 cells treated with non-targeting siRNA or siRNA targeting PPARGC1A. 24 hours post-transfection, cells were also treated with either DMSO or 500 nM lapatinib for 24 hours.

2022-09-26 | E-MTAB-10317 | biostudies-arrayexpress

ChIP-seq of HNF4A, PPARGC1A and H3K27ac in oesophageal adenocarcinoma OE19 cells treated with lapatinib

Project description:ChIP-seq of HNF4A, PPARGC1A and H3K27ac in oesophageal adenocarcinoma OE19 cells treated with lapatinib

| PRJEB44106 | ENA